Drugs that contain Varenicline Tartrate

1. Drug name - CHANTIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6890927 PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
May, 2022

(4 months ago)

US7265119 PF PRISM CV Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Aug, 2022

(a month ago)

CN1509174A PF PRISM CV 5, 8, 14-Aminosteroid, Triaza-Tetracyclo [10.3.1.0
Apr, 2022

(5 months ago)

CN100370987C PF PRISM CV 5, 8, 14-Aminosteroid, Triaza-Tetracyclo [10.3.1.0. 2.11. 0. 4.9]--2 (11), 3, 5, 7, 9, - Pentaene-Tartrate
Apr, 2022

(5 months ago)

IN200300863P3 PF PRISM CV Compound Of 5,8,14-Triazatracyclo[10.3.1.02.11.04.9]-Hexadeca-2(11),3,5,7,9-Pentaene
Apr, 2022

(5 months ago)

IN204091B PF PRISM CV Compound Of 5,8,14-Triazatracyclo[10.3.1.02.11.04.9]-Hexadeca-2(11),3,5,7,9-Pentaene
Apr, 2022

(5 months ago)

EP1392307B1 PF PRISM CV Tartrate Salts Of 5,8,14-Triazatetracyclo¬10.3.1.02,11.04,9-Hexadeca-2(11),3,5,7,9-Pentaene
Apr, 2022

(5 months ago)

EP1392307A1 PF PRISM CV Tartrate Salts Of 5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]-Hexadeca-2(11),3,5,7,9-Pentaene
Apr, 2022

(5 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6890927

(Pediatric)

PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof Nov, 2022

(a month from now)

US7265119

(Pediatric)

PF PRISM CV Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof Feb, 2023

(4 months from now)

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG BASE TABLET;ORAL Prescription
EQ 1MG BASE TABLET;ORAL Prescription

2. Drug name - TYRVAYA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504644 OYSTER POINT PHARMA Methods of increasing tear production Oct, 2035

(13 years from now)

US11224598 OYSTER POINT PHARMA Methods of increasing lacrimal proteins Oct, 2035

(13 years from now)

US9504645 OYSTER POINT PHARMA Pharmaceutical formulations for treating ocular conditions Oct, 2035

(13 years from now)

US10456396 OYSTER POINT PHARMA Dry eye treatments Oct, 2035

(13 years from now)

US9597284 OYSTER POINT PHARMA Dry eye treatments Oct, 2035

(13 years from now)

US9532944 OYSTER POINT PHARMA Methods of improving ocular discomfort Oct, 2035

(13 years from now)

Treatment: Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 0.03MG BASE/SPRAY SOLUTION;NASAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.